For a great many people the question is simply whether they have to inject. If that is the deciding factor, this comparison is short. But it is worth understanding what the tablet costs in expected results, because the difference is real and the decision is easier to make well with the number in front of you.
The two treatments
Wegovy is semaglutide given as a once-weekly injection with a pen, stored in the fridge, and it has been available in the UK for some time with a substantial body of real-world use behind it. Orforglipron is a once-daily tablet stored at room temperature, authorised on 10 August 2026 and not yet launched here. Both are GLP-1 receptor agonists, so both work by reducing appetite, slowing stomach emptying and supporting blood sugar control, and the subjective experience of reduced appetite and quieter food thoughts is broadly similar.
Effectiveness
Semaglutide at the weight-management dose produced average weight loss of around 15% of body weight over 68 weeks in its main trial, against roughly 2% on placebo. Orforglipron produced around 11% over 72 weeks in ATTAIN-1. The difference is meaningful without being dramatic: both comfortably clear the 10% threshold at which health improvements become reliable, and both sit well below what tirzepatide achieved. Individual variation within each trial was wide in both directions, which matters, because an average tells you what a group did rather than what you will do.
The practical differences
A weekly injection means one action a week and six days of not thinking about it, which suits people who would rather not have a daily medicine at all. It also means keeping pens refrigerated, planning around travel, carrying a cool bag, dealing with sharps disposal, and learning an injection technique. A daily tablet means remembering something every day, but nothing else: no fridge, no needles, no disposal, no travel planning beyond packing the container. Which of these is the greater inconvenience genuinely differs from person to person, and it is worth being honest with yourself about which one you would actually keep up.
Side effects
Both share the GLP-1 profile of digestive effects, concentrated around starting and dose increases and settling with time. The main difference is rhythm rather than severity. A weekly injection delivers a peak that some people notice in the days immediately after, producing a recognisable weekly pattern; a daily tablet spreads exposure more evenly, which some find easier and others find simply constant. Both carry the same uncommon risks around pancreatitis and gallbladder problems, and both require the same assessment of medical history before starting.
What happens if you miss a dose
This favours the tablet. A missed weekly injection is a larger event, with rules about how late it can still be taken and when to skip to the next scheduled dose, and a missed week leaves a real gap. A missed daily tablet is corrected the following day with little consequence. Set against that, the tablet has to be remembered 365 times a year rather than 52, so the risk shifts from occasional large gaps to frequent small ones. Anyone who knows they are unreliable with daily medicines should weigh that honestly.
Getting started
The first weeks look different for each. Starting an injection involves being shown the technique, learning to handle a pen and a needle, arranging fridge space and sorting out sharps disposal, and for most people the apprehension beforehand exceeds the difficulty of doing it. Starting a tablet involves swallowing a tablet. Both then move through months of dose escalation with a difficult few days after each step, so the escalation experience is broadly comparable. Where the tablet keeps its advantage is that the practical overhead never really goes away with an injection: the fridge, the pens and the disposal continue for as long as treatment does.
Track record
Semaglutide has been in widespread use for years, across very large numbers of people, which means its uncommon effects are far better characterised than those of a medicine authorised in August 2026. This is not a criticism of orforglipron, whose trial evidence is substantial, but it is a genuine difference. With any newly authorised medicine, the full picture of rare effects and long-term patterns fills in through real-world use, and the MHRA has said it will keep the class under close review.
Beyond weight: what each is licensed to do
Semaglutide has accumulated authorisations and evidence beyond weight management, including in type 2 diabetes and, in the injectable form, evidence relating to cardiovascular risk in certain groups. Orforglipron is authorised for weight management and for blood sugar control in insufficiently controlled type 2 diabetes, which is a substantial pair of indications for a newly approved medicine but a shorter list. For someone whose situation involves more than weight alone, and particularly where cardiovascular risk is part of the picture, the breadth of evidence behind a treatment can matter as much as its weight-loss average. That is a question for a prescriber who can see your full history rather than something to settle from an article.
Which to choose
If injecting is acceptable and the priority is results, Wegovy has the better average and the longer record, and it is available now. If injecting is the obstacle, orforglipron will offer a route to treatment at a somewhat lower expected result, once it launches. And if you are already doing well on Wegovy, the arrival of a tablet with lower published results is not a reason to change. The more interesting future question is maintenance: whether people who reach their target on an injection might move to a tablet to hold it, which is being studied and looks promising, but is a conversation for when the product is actually available.
